2024-10-29 - Analysis Report
## Thermo Fisher Scientific Inc (TMO) Stock Analysis Report

**1. Performance Comparison:**

Thermo Fisher Scientific Inc (TMO) has outperformed the S&P 500 (VOO) with a cumulative return of **215.71%** compared to the S&P 500's **136.36%**. This represents a **79.35%** difference in returns, placing it at the **37.17%** percentile of historical performance relative to the S&P 500.  

**Company Overview:** Thermo Fisher Scientific Inc. is a global leader in providing scientific research, analytical instruments, reagents, consumables, and software services.

**2. Recent Price Movement:**

* **Last Close:** $552.54
* **5-day Moving Average:** $565.43
* **20-day Moving Average:** $591.44
* **60-day Moving Average:** $603.19

TMO is currently trading below its 5-day, 20-day, and 60-day moving averages, indicating potential downward pressure.

**3. Technical Indicators:**

* **RSI:** 26.38 (oversold territory)
* **PPO:** -0.87 (bearish signal)
* **Delta_Previous_Relative_Divergence:** -18.31 (negative, indicating short-term downtrend)
* **Expected Return:** 46.94% (potential long-term outperformance compared to the S&P 500)

The RSI and PPO suggest oversold conditions and bearish sentiment. The negative relative divergence reinforces a potential short-term decline. However, the long-term expected return remains strong, suggesting potential for future growth. 

**4. Recent Earnings and Outlook:**

| Date       | EPS     | Revenue      |
|------------|---------|---------------|
| 2024-08-02 | $4.05    | $10.54B      |
| 2024-05-03 | $3.47    | $10.35B      |
| 2023-11-03 | $4.44    | $10.57B      |
| 2023-08-04 | $3.53    | $10.69B      |
| 2024-08-02 | $3.53    | $10.69B      |

TMO's most recent earnings report for Q2 2024 (August 2nd) reported EPS of $4.05 and revenue of $10.54B, surpassing analyst estimates of $3.89 and $10.45B respectively.  This positive earnings beat indicates strong performance despite a challenging macroeconomic environment. 

**5. Financial Trends Analysis:**

| Item               | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|--------------------|---------------|---------------|---------------|
| Revenue            | $10.54B         | $10.35B         | $10.89B         | 
| Gross Profit       | $4.35B          | $4.21B          | $4.39B          | 
| Gross Margin %     | 41.24%          | 40.65%          | 40.35%          | 
| Operating Income   | $1.90B          | $1.69B          | $1.93B          | 
| Operating Margin % | 18.00%          | 16.35%          | 17.77%          | 
| Net Income         | $1.55B          | $1.33B          | $1.63B          | 
| Net Margin %       | 14.69%          | 12.84%          | 14.97%          | 
| EPS                | $4.05           | $3.48           | $4.27           | 
| ROE %              | 3.26%           | 2.92%           | 3.49%           | 
| Total Assets       | $98.50B         | $97.09B         | $98.73B         | 
| Total Liabilities  | $50.96B         | $51.47B         | $51.88B         | 
| Total Equity       | $47.43B         | $45.52B         | $46.73B         | 
| Operating Cash Flow | $1.96B          | $1.25B          | $3.72B          | 
| Capital Expenditure | $-0.30B         | $-0.35B         | $-0.41B         | 

TMO has consistently shown strong financial performance with robust revenue growth and healthy profit margins. The company's financial health remains stable, with strong cash flow and consistent investments in research and development.

**6. News and Recent Issues:**

**Recent Market Outlook:** TMO is expected to benefit from continued growth in the healthcare and life sciences sectors. The company's diversified portfolio and strong brand position are key drivers for sustained growth in the future.

**Analyst Opinions and Performance Highlights:** The majority of analysts have a "buy" rating on TMO, citing the company's robust growth potential and strong track record. FINBOLD analysts highlight TMO's strong earnings growth and solid cash flow generation as key indicators of a healthy company.

**7. Comprehensive Analysis:**

TMO is a leading player in the scientific instruments and services market, with a strong track record of financial performance. The company has shown sustained growth and profitability, with recent earnings exceeding analyst expectations. The stock is currently trading below its moving averages, suggesting short-term weakness, but its strong long-term prospects and positive analyst sentiment suggest a potential for future upside. However, it's important to note that TMO is currently trading in oversold territory, indicating a potential for further downside.

**8. Recommendation:**

TMO presents an attractive investment opportunity for long-term investors seeking exposure to the healthcare and life sciences sectors. The company's strong financials, growth potential, and positive industry outlook suggest that TMO is well-positioned for future growth. However, the current oversold condition suggests investors may want to wait for a pullback before initiating a position. 

**Disclaimer:** This report is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and due diligence before making any investment decisions. 
